Skip to main navigation Skip to search Skip to main content

Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C

  • Chih Hung Chen
  • , Chuan Mo Lee
  • , Chien Hung Chen
  • , Tsung Hui Hu
  • , Jing Houng Wang
  • , Chao Hung Hung*
  • , Ching Hu Chung
  • , Sheng Nan Lu
  • *Corresponding author for this work
  • Chang Gung University
  • Tzu Chi University

Research output: Contribution to journal › Journal Article › peer-review

15 Scopus citations

Abstract

Background: Chronic hepatitis C (CHC) is frequently associated with the presence of serum autoantibodies. The prevalence and clinical relevance of serum autoantibodies in CHC patients and their influence on antiviral treatment have not been well established. Methods: From February 1999 to July 2004, 460 consecutive adult patients with CHC were studied. Antinuclear antibody (ANA) and smooth muscle antibody (SMA) were determined by indirect immunofluorescence. The presence of these antibodies was related to patient characteristics and to the outcome of 24 weeks of therapy with interferon (IFN) alfa-2b (n = 376) or pegylatedIFN alfa-2b (n = 84) plus ribavirin. Results: The prevalence of ANA and SMA was 7.4% and 19.3%, respectively. Seropositivity for ANA and/or SMA was associated with old age and high aspartate aminotransferase (AST) levels. The rates of sustained virological response and early withdrawal of therapy were comparable between autoantibody-positive and -negative patients. None of the autoantibody-positive patients experienced a flare-up of transaminase during treatment, or developed severe systemic autoimmune disease. Conclusion: Serum ANA and/or SMA-positive HCV-infected patients are older, and have higher disease activity and severity than their negative counterparts. However, the presence of ANA or SMA did not influence the response to combination antiviral therapy, which is safe and effective in autoantibody - positive CHC patients.

Original languageEnglish
Pages (from-to)258-265
Number of pages8
JournalChang Gung Medical Journal
Volume33
Issue number3
StatePublished - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antinuclear antibody
  • Antiviral therapy
  • Hepatitis C
  • Smooth muscle antibody
  • Sustained virological response

Fingerprint

Dive into the research topics of 'Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C'. Together they form a unique fingerprint.

Cite this